436 related articles for article (PubMed ID: 22815639)
1. SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).
Vistica BP; Shi G; Nugent L; Tan C; Altman A; Gery I
Mol Vis; 2012; 18():1858-64. PubMed ID: 22815639
[TBL] [Abstract][Full Text] [Related]
2. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
3. SLAT/Def6 plays a critical role in the development of Th17 cell-mediated experimental autoimmune encephalomyelitis.
Canonigo-Balancio AJ; Fos C; Prod'homme T; Bécart S; Altman A
J Immunol; 2009 Dec; 183(11):7259-67. PubMed ID: 19915062
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis.
Takeuchi M; Yokoi H; Tsukahara R; Sakai J; Usui M
Jpn J Ophthalmol; 2001; 45(5):463-9. PubMed ID: 11583666
[TBL] [Abstract][Full Text] [Related]
5. [Effects of exogenous interleukin-2, interleukin-23 on differentiation of IRBP 1-20-specific T cells toward Th1 and Th17 and comparison of the pathogenicity of IRBP 1-20-specific T cells].
Li Y; Cui Y; Bi HS; Wang Y; Li J; Wang XR
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):224-9. PubMed ID: 23866703
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells.
Bing SJ; Lyu C; Xu B; Wandu WS; Hinshaw SJ; Furumoto Y; Caspi RR; Gadina M; Gery I
Mol Vis; 2020; 26():641-651. PubMed ID: 33088168
[TBL] [Abstract][Full Text] [Related]
7. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells.
Hou W; Wu Y; Sun S; Shi M; Sun Y; Yang C; Pei G; Gu Y; Zhong C; Sun B
J Immunol; 2003 Feb; 170(4):1728-36. PubMed ID: 12574336
[TBL] [Abstract][Full Text] [Related]
8. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
9. Comparative Analysis of the Interphotoreceptor Retinoid Binding ProteinInduced Models of Experimental Autoimmune Uveitis in B10.RIII versus C57BL/6 Mice.
Chen Y; Chen Z; Chong WP; Wu S; Wang W; Zhou H; Chen J
Curr Mol Med; 2018; 18(9):602-611. PubMed ID: 30636608
[TBL] [Abstract][Full Text] [Related]
10. Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response.
Wandu WS; Tan C; Ogbeifun O; Vistica BP; Shi G; Hinshaw SJ; Xie C; Chen X; Klinman DM; Cai H; Gery I
PLoS One; 2015; 10(6):e0128906. PubMed ID: 26067490
[TBL] [Abstract][Full Text] [Related]
11. Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis.
Silver PB; Horai R; Chen J; Jittayasothorn Y; Chan CC; Villasmil R; Kesen MR; Caspi RR
J Immunol; 2015 Apr; 194(7):3011-9. PubMed ID: 25716996
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
13. ITE, a novel endogenous nontoxic aryl hydrocarbon receptor ligand, efficiently suppresses EAU and T-cell-mediated immunity.
Nugent LF; Shi G; Vistica BP; Ogbeifun O; Hinshaw SJ; Gery I
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7463-9. PubMed ID: 24150760
[TBL] [Abstract][Full Text] [Related]
14. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
15. The anti-IRBP IgG1 and IgG2a response does not correlate with susceptibility to experimental autoimmune uveitis.
de Moraes LV; Martins GA; Flangini M; Ibañez OM; Sant'Anna OA; Rizzo LV
Braz J Med Biol Res; 2006 Jun; 39(6):773-83. PubMed ID: 16751983
[TBL] [Abstract][Full Text] [Related]
16. Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.
Keino H; Takeuchi M; Usui Y; Hattori T; Yamakawa N; Kezuka T; Sakai JI; Usui M
Br J Ophthalmol; 2007 Jan; 91(1):105-10. PubMed ID: 16943228
[TBL] [Abstract][Full Text] [Related]
17. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Kwak HJ; Yang YS; Pae HO; Kim YM; Chung HT
Mol Cells; 2001 Oct; 12(2):178-84. PubMed ID: 11710518
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Okada AA
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1548-56. PubMed ID: 20861477
[TBL] [Abstract][Full Text] [Related]
19. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of DR3 expression in CD4⁺ T cells promotes secretion of IL-17 in experimental autoimmune uveitis.
Qin T
Mol Vis; 2011; 17():3486-93. PubMed ID: 22219644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
